ATHA Insider Transactions
| Transaction Date (SEC Report ) |
Reporting Name | Relationship | Shrs. Owned | Type | Acq./Disp. | Shrs. Transacted | Price() | Amount() |
|---|---|---|---|---|---|---|---|---|
| 2023-01-27 | Litton Mark James | director, officer: Chief Executive Officer | 425,000 | A-Award | A | 425,000 | 4.11 | 1,746,750.00 |
| 2023-01-19 | MILESON GLENNA | officer: Chief Financial Officer | 150,000 | A-Award | A | 150,000 | 3.37 | 505,500.00 |
| 2023-01-19 | MOEBIUS HANS | officer: Chief Medical Officer | 200,000 | A-Award | A | 200,000 | 3.37 | 674,000.00 |
| 2023-01-19 | Worthington Mark | officer: General Counsel | 150,000 | A-Award | A | 150,000 | 3.37 | 505,500.00 |
| 2023-01-19 | Lenington Rachel | officer: Chief Operating Officer | 200,000 | A-Award | A | 200,000 | 3.37 | 674,000.00 |
| 2023-01-19 | CHURCH KEVIN | officer: Executive VP, Research | 150,000 | A-Award | A | 150,000 | 3.37 | 505,500.00 |
| 2022-12-28 | MILESON GLENNA | officer: Chief Financial Officer | 159,930 | P-Purchase | A | 50,000 | 2.85 | 142,250.00 |
| 2022-12-02 | Romano Kelly A | director | 38,315 | P-Purchase | A | 30,000 | 3.29 | 98,700.00 |
| 2022-11-18 | Litton Mark James | director, officer: Chief Executive Officer | 129,217 | A-Award | A | 662 | 2.74 | 1,813.88 |
| 2022-11-18 | CHURCH KEVIN | officer: Executive VP, Research | 62,052 | A-Award | A | 657 | 2.74 | 1,800.18 |
| 2022-11-18 | MILESON GLENNA | officer: Chief Financial Officer | 109,930 | A-Award | A | 763 | 2.74 | 2,090.62 |
| 2022-11-15 | MOEBIUS HANS | officer: Chief Medical Officer | 65,836 | P-Purchase | A | 5,000 | 3.29 | 16,442.00 |
| 2022-10-28 | CHURCH KEVIN | officer: Executive VP, Research | 6,410 | M-Exempt | D | 3,700 | 1.35 | 4,995.00 |
| 2022-10-28 | CHURCH KEVIN | officer: Executive VP, Research | 61,395 | M-Exempt | A | 3,700 | 1.35 | 4,995.00 |
| 2022-10-13 | MOEBIUS HANS | officer: Chief Medical Officer | 7,882 | M-Exempt | D | 7,881 | 1.35 | 10,639.35 |
| 2022-10-13 | MOEBIUS HANS | officer: Chief Medical Officer | 60,836 | M-Exempt | A | 7,881 | 1.35 | 10,639.35 |
| 2022-06-30 | PERCEPTIVE ADVISORS LLC | director, 10 percent owner | 4,797,278 | P-Purchase | A | 1,101,362 | 2.99 | 3,293,072.38 |
| 2022-06-29 | PERCEPTIVE ADVISORS LLC | director, 10 percent owner | 3,695,916 | P-Purchase | A | 270,000 | 2.99 | 807,300.00 |
| 2022-06-28 | MOEBIUS HANS | officer: Chief Medical Officer | 52,955 | P-Purchase | A | 10,000 | 2.88 | 28,800.00 |
| 2022-06-23 | Worthington Mark | officer: General Counsel | 19,097 | S-Sale | D | 2,614 | 2.69 | 7,031.66 |
| 2022-06-23 | Litton Mark James | director, officer: Chief Executive Officer | 128,555 | S-Sale | D | 7,960 | 2.69 | 21,412.40 |
| 2022-06-23 | MILESON GLENNA | officer: Chief Financial Officer | 109,167 | S-Sale | D | 2,614 | 2.69 | 7,031.66 |
| 2022-06-23 | Lenington Rachel | officer: Chief Operating Officer | 5,807 | S-Sale | D | 4,193 | 2.69 | 11,279.17 |
| 2022-06-23 | CHURCH KEVIN | officer: Executive VP, Research | 57,695 | S-Sale | D | 2,614 | 2.69 | 7,031.66 |
| 2022-06-22 | Worthington Mark | officer: General Counsel | 21,711 | A-Award | A | 10,000 | 0.00 | 0.00 |
| 2022-06-22 | MOEBIUS HANS | officer: Chief Medical Officer | 42,955 | A-Award | A | 10,000 | 0.00 | 0.00 |
| 2022-06-22 | Litton Mark James | director, officer: Chief Executive Officer | 136,515 | A-Award | A | 20,000 | 0.00 | 0.00 |
| 2022-06-22 | MILESON GLENNA | officer: Chief Financial Officer | 111,781 | A-Award | A | 10,000 | 0.00 | 0.00 |
| 2022-06-22 | Lenington Rachel | officer: Chief Operating Officer | 10,000 | A-Award | A | 10,000 | 0.00 | 0.00 |
| 2022-06-22 | CHURCH KEVIN | officer: Executive VP, Research | 60,309 | A-Award | A | 10,000 | 0.00 | 0.00 |
| 2022-06-08 | CHURCH KEVIN | officer: Executive VP, Research | 10,110 | M-Exempt | D | 2,500 | 1.35 | 3,375.00 |
| 2022-06-08 | CHURCH KEVIN | officer: Executive VP, Research | 50,309 | M-Exempt | A | 2,500 | 1.35 | 3,375.00 |
| 2022-05-20 | Kosacz Barbara | director | 13,871 | A-Award | A | 13,871 | 8.93 | 123,868.03 |
| 2022-05-20 | Panzara Michael A. | director | 2,311 | A-Award | A | 2,311 | 8.93 | 20,637.23 |
| 2022-05-20 | FLUKE JOHN M JR | director | 13,871 | A-Award | A | 13,871 | 8.93 | 123,868.03 |
| 2022-05-20 | Romano Kelly A | director | 13,871 | A-Award | A | 13,871 | 8.93 | 123,868.03 |
| 2022-05-20 | PICKERING GRANT | director | 3,467 | A-Award | A | 3,467 | 8.93 | 30,960.31 |
| 2022-05-20 | JOHNSON JAMES A | director | 13,871 | A-Award | A | 13,871 | 8.93 | 123,868.03 |
| 2022-05-20 | EDELMAN JOSEPH | director | 13,871 | A-Award | A | 13,871 | 8.93 | 123,868.03 |
| 2022-05-20 | PERCEPTIVE ADVISORS LLC | director, 10 percent owner | 13,871 | A-Award | A | 13,871 | 8.93 | 123,868.03 |
| 2022-05-18 | Worthington Mark | officer: General Counsel | 11,711 | A-Award | A | 3,396 | 7.06 | 23,975.76 |
| 2022-05-18 | MOEBIUS HANS | officer: Chief Medical Officer | 32,955 | A-Award | A | 1,699 | 7.06 | 11,994.94 |
| 2022-05-18 | Litton Mark James | director, officer: Chief Executive Officer | 116,515 | A-Award | A | 757 | 7.06 | 5,344.42 |
| 2022-05-18 | MILESON GLENNA | officer: Chief Financial Officer | 101,781 | A-Award | A | 1,721 | 7.06 | 12,150.26 |
| 2022-05-18 | CHURCH KEVIN | officer: Executive VP, Research | 47,809 | A-Award | A | 243 | 7.06 | 1,715.58 |
| 2022-04-11 | MILESON GLENNA | officer: Chief Financial Officer | 167,000 | M-Exempt | D | 3,000 | 10.64 | 31,920.00 |
| 2022-04-11 | MILESON GLENNA | officer: Chief Financial Officer | 100,060 | M-Exempt | A | 3,000 | 10.64 | 31,920.00 |
| 2022-03-31 | Romano Kelly A | director | 8,315 | P-Purchase | A | 8,000 | 13.11 | 104,880.00 |
| 2022-03-18 | Panzara Michael A. | director | 27,742 | A-Award | A | 27,742 | 10.62 | 294,620.04 |
| 2022-02-18 | CHURCH KEVIN | officer: Executive VP, Research | 0 | M-Exempt | D | 3,152 | 1.19 | 3,750.88 |
| 2022-02-18 | CHURCH KEVIN | officer: Executive VP, Research | 47,566 | M-Exempt | A | 3,152 | 1.19 | 3,750.88 |
| 2022-01-27 | Litton Mark James | director, officer: Chief Executive Officer | 400,000 | A-Award | A | 400,000 | 9.91 | 3,964,000.00 |
| 2022-01-27 | PICKERING GRANT | director | 27,742 | A-Award | A | 27,742 | 9.91 | 274,923.22 |
| 2022-01-18 | Lenington Rachel | officer: Chief Operating Officer | 180,000 | A-Award | A | 180,000 | 10.64 | 1,915,200.00 |
| 2022-01-18 | MILESON GLENNA | officer: Chief Financial Officer | 170,000 | A-Award | A | 170,000 | 10.64 | 1,808,800.00 |
| 2022-01-18 | CHURCH KEVIN | officer: Executive VP, Research | 100,000 | A-Award | A | 100,000 | 10.64 | 1,064,000.00 |
| 2022-01-18 | MOEBIUS HANS | officer: Chief Medical Officer | 180,000 | A-Award | A | 180,000 | 10.64 | 1,915,200.00 |
| 2022-01-18 | Worthington Mark | officer: General Counsel | 150,000 | A-Award | A | 150,000 | 10.64 | 1,596,000.00 |
| 2022-01-04 | MILESON GLENNA | officer: Chief Financial Officer | 0 | M-Exempt | D | 6,305 | 1.35 | 8,511.75 |
| 2022-01-04 | MILESON GLENNA | officer: Chief Financial Officer | 97,060 | M-Exempt | A | 6,305 | 1.35 | 8,511.75 |
| 2021-11-18 | Litton Mark James | director, officer: Chief Executive Officer | 115,758 | A-Award | A | 885 | 12.51 | 11,071.35 |
| 2021-11-18 | CHURCH KEVIN | officer: Executive VP, Research | 44,414 | A-Award | A | 96 | 12.51 | 1,200.96 |
| 2021-11-18 | MOEBIUS HANS | officer: Chief Medical Officer | 31,256 | A-Award | A | 829 | 12.51 | 10,370.79 |
| 2021-11-18 | MILESON GLENNA | officer: Chief Financial Officer | 90,755 | A-Award | A | 931 | 12.51 | 11,646.81 |
| 2021-11-03 | Lenington Rachel | officer: Chief Operating Officer | 150,000 | A-Award | A | 150,000 | 15.34 | 2,301,000.00 |
| 2021-11-03 | Worthington Mark | officer: General Counsel | 150,000 | A-Award | A | 150,000 | 15.34 | 2,301,000.00 |
| 2021-08-17 | Litton Mark James | officer: Chief Operating Officer | 114,873 | M-Exempt | A | 50,440 | 1.35 | 68,094.00 |
| 2021-08-17 | Litton Mark James | officer: Chief Operating Officer | 100,880 | M-Exempt | D | 50,440 | 1.35 | 68,094.00 |
| 2021-07-21 | MOEBIUS HANS | officer: Chief Medical Officer | 0 | M-Exempt | D | 12,610 | 1.35 | 17,023.50 |
| 2021-07-21 | MOEBIUS HANS | officer: Chief Medical Officer | 30,427 | M-Exempt | A | 15,762 | 1.35 | 21,278.70 |
| 2021-07-21 | MOEBIUS HANS | officer: Chief Medical Officer | 14,665 | M-Exempt | A | 12,610 | 1.35 | 17,023.50 |
| 2021-07-21 | MOEBIUS HANS | officer: Chief Medical Officer | 15,763 | M-Exempt | D | 15,762 | 1.35 | 21,278.70 |
| 2021-06-15 | FLUKE JOHN M JR | director | 144,884 | J-Other | A | 1,000 | 0.00 | 0.00 |
| 2021-06-15 | FLUKE JOHN M JR | director | 3,731 | J-Other | D | 3,000 | 0.00 | 0.00 |
| 2021-06-10 | MILESON GLENNA | officer: Chief Financial Officer | 89,824 | M-Exempt | A | 6,305 | 1.35 | 8,511.75 |
| 2021-06-10 | MILESON GLENNA | officer: Chief Financial Officer | 6,305 | M-Exempt | D | 6,305 | 1.35 | 8,511.75 |
| 2021-06-08 | CHURCH KEVIN | officer: Vice President of Discovery | 0 | M-Exempt | D | 3,152 | 1.04 | 3,278.08 |
| 2021-06-08 | CHURCH KEVIN | officer: Vice President of Discovery | 44,133 | M-Exempt | A | 3,152 | 1.04 | 3,278.08 |
| 2021-06-08 | CHURCH KEVIN | officer: Vice President of Discovery | 44,318 | M-Exempt | A | 3,152 | 1.04 | 3,278.08 |
| 2021-05-28 | JOHNSON JAMES A | director | 13,871 | A-Award | A | 13,871 | 19.94 | 276,587.74 |
| 2021-05-28 | FLUKE JOHN M JR | director | 13,871 | A-Award | A | 13,871 | 19.94 | 276,587.74 |
| 2021-05-28 | Yamada Tadataka | director | 13,871 | A-Award | A | 13,871 | 19.94 | 276,587.74 |
| 2021-05-28 | PERCEPTIVE ADVISORS LLC | director, 10 percent owner | 13,871 | A-Award | A | 13,871 | 19.94 | 276,587.74 |
| 2021-05-28 | EDELMAN JOSEPH | director, 10 percent owner | 13,871 | A-Award | A | 13,871 | 19.94 | 276,587.74 |
| 2021-05-18 | MOEBIUS HANS | officer: Chief Medical Officer | 2,055 | A-Award | A | 2,055 | 14.45 | 29,694.75 |
| 2021-05-18 | Litton Mark James | officer: Chief Operating Officer | 64,433 | A-Award | A | 867 | 14.45 | 12,528.15 |
| 2021-05-18 | CHURCH KEVIN | officer: Vice President of Discovery | 41,166 | A-Award | A | 185 | 14.45 | 2,673.25 |
| 2021-05-18 | MILESON GLENNA | officer: Chief Financial Officer | 83,519 | A-Award | A | 1,554 | 14.45 | 22,455.30 |
| 2021-03-04 | Kosacz Barbara | director | 27,742 | A-Award | A | 27,742 | 19.29 | 535,143.18 |
| 2021-02-18 | Litton Mark James | officer: Chief Operating Officer | 85,000 | A-Award | A | 85,000 | 21.15 | 1,797,750.00 |
| 2021-02-18 | CHURCH KEVIN | officer: Vice President of Discovery | 20,000 | A-Award | A | 20,000 | 21.15 | 423,000.00 |
| 2021-02-18 | KAWAS LEEN | director, officer: President & CEO | 231,000 | A-Award | A | 231,000 | 21.15 | 4,885,650.00 |
| 2021-02-18 | MILESON GLENNA | officer: Chief Financial Officer | 73,500 | A-Award | A | 73,500 | 21.15 | 1,554,525.00 |
| 2021-02-18 | MOEBIUS HANS | officer: Chief Medical Officer | 72,000 | A-Award | A | 72,000 | 21.15 | 1,522,800.00 |
| 2021-02-03 | FLUKE JOHN M JR | director | 140,101 | M-Exempt | A | 25,220 | 1.19 | 30,011.80 |
| 2021-02-03 | FLUKE JOHN M JR | director | 143,884 | M-Exempt | A | 3,783 | 1.35 | 5,107.05 |
| 2021-02-03 | FLUKE JOHN M JR | director | 0 | M-Exempt | D | 25,220 | 1.19 | 30,011.80 |
| 2021-01-25 | PERCEPTIVE ADVISORS LLC | director, 10 percent owner | 3,425,916 | P-Purchase | A | 311,111 | 22.50 | 6,999,997.50 |
| 2020-12-22 | Romano Kelly A | director | 315 | L-Small | A | 315 | 31.74 | 9,999.08 |
| 2020-12-11 | Romano Kelly A | director | 27,742 | A-Award | A | 27,742 | 29.41 | 815,892.22 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Group doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Group or anyone involved with Discounting Cash Flows Group will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.